In addition to their contraceptive effect, modern contraceptives are known to prevent and treat certain gynecological diseases. One of the important points in the treatment of infertility is the problem of ovulation. Irregular menstruation responds to abnormal follicular development and ovulation, and much of the process of promoting ovulation must be based on regular menstruation, so oral short-acting contraceptives play an important role in the treatment of infertility. To summarize, there are several main uses. 1, adjusting the menstrual cycle and treating abnormal uterine bleeding 1.1 Adjusting the menstrual cycle Adjusting the menstrual cycle, disorders of the menstrual cycle can be manifested as cycle disorders, prolonged menstrual period and increased menstrual flow. First of all, after excluding organic lesions, the menstrual cycle can be controlled by compound short-acting oral contraceptive pills, which are generally available for 3 to 6 cycles. Withdrawal bleeding from the drug occurs 2 to 3 days after stopping the drug, and this cycle is very regular with fewer days of menstruation and less menstrual blood. 1.2 Treatment of dysfunctional uterine bleeding (included in the latest name “abnormal uterine bleeding”) Dysfunctional uterine bleeding, experts from the Endocrinology Group and the Menopause Group of the Obstetrics and Gynecology Section of the Chinese Medical Association have spent nearly 3 years collecting relevant literature and opinions from various parties, and have developed the Clinical Guidelines for the Diagnosis and Treatment of Dysfunctional Uterine Bleeding after many discussions The guideline mentions three commonly used treatments for dysfunctional bleeding. The guideline mentions three commonly used medication methods for treating dysfunctional uterine bleeding. The endometrial shedding method refers to the method of progesterone treatment; the endometrial growth and repair method, which gives a sufficient amount of estrogen to let the shed endometrium grow up and synchronize the endometrium; and the endometrial atrophy method, which is commonly used for menopausal transition bleeding, is to stop bleeding with a high dose of progesterone. One of the endometrial growth and repair methods is commonly used with modern contraceptive pills. Estrogen in modern contraceptive formulations can maintain endometrial growth, increase endometrial thickness, prevent breakthrough bleeding, and inhibit pituitary FSH secretion; progesterone can transform (protect) the endometrium so that the endometrial gland secretion, interstitial metaplasia-like atrophy, and inhibit LH secretion. For example, the use of deoxypregnene ethinyl estradiol tablets (Momoflower), 3 tablets / day, after 3 days, reduce the amount of 2 tablets / day, and then after 3 days, reduce the amount of 1 tablet / day, a total of 21 days to maintain the next menstrual period after stopping the drug. Generally, the bleeding can be stopped within 4 to 6 hours after taking the medicine on the first day. However, you should not stop the medication after the bleeding stops, but should complete the program, otherwise the hormone withdrawal may cause bleeding again. During the medication period, you can take vitamin B6 and vitamin C orally every day, and should not take antibiotics (which can interfere with the hormone’s hepatic and intestinal circulation). Can also be used with pregnenolone ethinyl estradiol tablets (Mintin even, each tablet contains pregnenolone 75 μg, ethinyl estradiol 30 μg); ethinyl estradiol cyproterone tablets (daing-35, each tablet contains cyproterone acetate 2 mg and ethinyl estradiol 0.035 mg); or compound levon 18 methyl ethinyl ketolone (each tablet contains levon 18 methyl ethinyl ketolone 0115 mg, ethinyl estradiol 30 μg); compound levonorgestrel and drospirenone-ethinylestradiol tablets (Eucerin, each tablet contains drospirenone 3 mg, ethinylestradiol 30 μg). Irregular menstrual cycles are often a reflection of problems with follicular development, which inevitably affects pregnancy. If you have fertility requirements, you can use ovulation stimulant to promote ovulation on the 3rd-5th day of withdrawal bleeding after controlling the cycle with medication, monitoring follicular development, guided coitus, artificial insemination or super-ovulation stimulation + in vitro fertilization, with a view to obtaining a pregnancy. 2.Lower LH, LH/FSH, T, improve the responsiveness of ovulation drugs This is mainly for polycystic ovary syndrome (PCOS) patients, PCOS patients with characteristic endocrine changes in high LH, LH/FSH, T, these “three highs” affect the development of follicles, resulting in ovulation disorders. Hyperandrogenemia inhibits follicular maturation, causing atresia of developing follicles, which prevents the formation of dominant follicles and leads to persistent anovulation. Excessive androgens are easily converted to estrone in adipose tissue, causing the estrone/estradiol ratio to rise, which both affects follicular development and feedback causes an increase in central secretion of LH, which elevates the LH/FSH ratio, leading to ovulation disorders. Hyperandrogenemia can also cause a decrease in sex hormone binding globulin (SHBG) levels and an increase in free testosterone, further affecting normal follicular growth, maturation and ovulation. In normal ovaries, when the follicle diameter increases to 9-10 mm, its granulosa cells secrete E2 under the action of LH, whereas in PCOS patients, when the follicle diameter increases to only 4 mm, LH induces the granulosa cells to secrete E2, i.e., the follicles of patients with PCOS are “aged” compared to normal follicles of the corresponding stage. High LH levels affect not only androgen synthesis in the ovaries, but also every stage of the reproductive process, including egg maturation, ovulation, fertilization and implantation. For those with high LH levels, if the high LH is not reduced first, the result of direct ovulation induction is often a high Gn dosage, a long medication duration, a high cycle cancellation rate, a low pregnancy rate, and a tendency to very early miscarriage even after conception, which may be related to the follicles of PCOS patients’ “aging”, and the ability of fertilization of these eggs is low, and the fertilization of the eggs after fertilization is low, and the fertilization of the eggs is low. This may be related to the “aging” of the follicles in patients with PCOS, as these eggs have a low ability to be fertilized, and a similarly low ability to attach after fertilization. The high potency progestogen contained in the compound oral contraceptive pill inhibits the secretion of pituitary gonadotropins, especially LH, and therefore the synthesis of ovarian androgens. It can also increase the concentration of blood SHBG, which leads to a decrease in free androgens and a decrease in the bioavailability of androgens, which in turn improves ovulation disorders in patients with PCOS and improves the responsiveness to ovulation-promoting drugs. In this regard, the first choice is Daying-35, but also can use Momoflurane, Mindin even and Yosmin and so on. Eliminate non-cancerous ovarian cysts Non-cancerous ovarian cysts, mainly follicular cysts, corpus luteum cysts, simple cysts and endometriotic cysts. Ovarian cysts are considered to be a contraindication to ovulation, and because they may increase in size with pregnancy, they should be eliminated as a first step in both ovulation and pregnancy planning. The first two of the non-congestive ovarian cysts described above are mostly associated with dysregulation of the hypothalamic-pituitary-ovarian axis, while the mechanism of the latter two is currently unclear. Compound contraceptives inhibit the hypothalamic-pituitary-ovarian axis, FSH and LH, and ovarian function is suppressed during drug administration. The suppression of ovulation reduces the occurrence of functional ovarian cysts, such as follicular cysts and corpus luteum cysts, and accelerates the shrinkage and disappearance of existing functional ovarian cysts. It takes 3 to 6 cycles of treatment, and most of the functional ovarian cysts can disappear within 3 cycles. 4.Improve the responsiveness of ovarian hypoplasia, rest the ovaries and protect the remaining follicles In suspected premature ovarian failure (POF) or older age (generally >40 years old), the ovarian reserve in the ovary is reduced, and the release of estrogen and inhibitory hormone is reduced, which leads to a high FSH, and at the same time, the excessive FSH accelerates the decline of ovarian function. This may be due to the “toxicity” of the high FSH environment to the surviving follicles: in normal female ovaries, during the development of the primordial follicle, the level of FSH receptors is a gradual process of increase, which is favorable to its ability to be recruited early in the follicle and to continue to develop. In patients with low ovarian reserve, although a small number of primordial follicles with the ability to continue to mature remain in the ovary, the high level of FSH in the patient’s body inhibits the increase in FSH receptor levels on the primordial follicle, resulting in the follicle failing to be recruited and degenerating. This is the so-called “toxic” effect of high levels of FSH on the follicle, and is one of the major reasons for the poor response to gonadotropins. The highly effective progestin component of oral contraceptives can inhibit the rise of FSH levels through negative feedback, and has the effect of “up-regulating” FSH receptors, thus protecting the remaining follicles and helping follicle recruitment, thus improving ovarian responsiveness. The protective effect of oral contraceptives may also be due to their inhibitory effect on ovulation, which may help to improve ovarian responsiveness to gonadotropins by giving the ovaries a “rest” before ovulation is induced. If the use of super-ovulation stimulation of down-regulation, then the use of short-acting oral contraceptives is generally normal menstrual cycle, one is conducive to the use of down-regulation drugs, and secondly, due to the short-acting oral contraceptives on the gonadotropic axis of the negative feedback effect, short-acting oral contraceptives have recently been thought to be able to partially or even completely replace the down-regulation of the role of GnRHa, reduce the dosage of GnRHa, so as to avoid the excessive inhibitory effect of GnRHa, enhance the ovarian response to Gonadotropin. and improve the ovarian responsiveness.